tbuckley/cabot-search huggingface dataset:
Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger — United States, 2024
Authors: A. Patricia Wodi, Neil Murthy, Veronica V. McNally, Matthew F. Daley, Sybil Cineas
Journal: MMWR Morbidity and Mortality Weekly Report (2024)

At its October 2023 meeting, the Advisory Committee on Immunization Practices* (ACIP) approved the Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger, United States, 2024. The child and adolescent immunization schedule, which can be found on the CDC immunization schedule website (https://www.cdc.gov/vaccines/schedules), is published annually to consolidate and summarize updates to ACIP recommendations on the vaccination of children and adolescents and to assist health care providers in implementing current ACIP recommendations. The 2024 immunization schedule includes several changes to the cover page, tables, notes, and appendix from the 2023 immunization schedule.
Childhood Trauma, Emotional Awareness, and Neural Correlates of Long-Term Nicotine Smoking
Authors: Annika Quam, Kathryn Biernacki, Thomas J. Ross, Betty Jo Salmeron, Amy C. Janes
Journal: JAMA Network Open (2024)

Temporal dynamic measures provide insight into the neurobiological properties of nicotine use. It is critical to determine whether brain-based measures are associated with substance use risk factors, such as childhood trauma-related emotion dysregulation.
Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer
Authors: Danish Memon, Adam J. Schoenfeld, Darwin Ye, George Fromm, Hira Rizvi, Xiang Zhang, Mohamed Reda Keddar, Divij Mathew, Kyung Jin Yoo, Jingya Qiu, Jayon Lihm, Jayalaksmi Miriyala, Jennifer L. Sauter, Jia Luo, Andrew Chow, Umesh K. Bhanot, Caroline McCarthy, Chad M. Vanderbilt, Cailian Liu, Mohsen Abu-Akeel, Andrew J. Plodkowski, Nicholas McGranahan, Marta Łuksza, Benjamin D. Greenbaum, Taha Merghoub, Ikbel Achour, J. Carl Barrett, Ross Stewart, Pedro Beltrao, Taylor H. Schreiber, Andy J. Minn, Martin L. Miller, Matthew D. Hellmann
Journal: Cancer Cell (2024)

Although immunotherapy with PD-(L)1 blockade is routine for lung cancer, little is known about acquired resistance. Among 1,201 patients with non-small cell lung cancer (NSCLC) treated with PD-(L)1 blockade, acquired resistance is common, occurring in >60% of initial responders. Acquired resistance shows differential expression of inflammation and interferon (IFN) signaling. Relapsed tumors can be separated by upregulated or stable expression of IFNγ response genes. Upregulation of IFNγ response genes is associated with putative routes of resistance characterized by signatures of persistent IFN signaling, immune dysfunction, and mutations in antigen presentation genes which can be recapitulated in multiple murine models of acquired resistance to PD-(L)1 blockade after in vitro IFNγ treatment. Acquired resistance to PD-(L)1 blockade in NSCLC is associated with an ongoing, but altered IFN response. The persistently inflamed, rather than excluded or deserted, tumor microenvironment of acquired resistance may inform therapeutic strategies to effectively reprogram and reverse acquired resistance.
Integrated proteogenomic characterization of glioblastoma evolution
Authors: Kyung-Hee Kim, Simona Migliozzi, Harim Koo, Jun-Hee Hong, Seung Min Park, Sooheon Kim, Hyung Joon Kwon, Seokjun Ha, Luciano Garofano, Young Taek Oh, Fulvio D'Angelo, Chan Il Kim, Seongsoo Kim, Ji Yoon Lee, Jiwon Kim, Jisoo Hong, Eun-Hae Jang, Bertrand Mathon, Anna-Luisa Di Stefano, Franck Bielle, Alice Laurenge, Alexey I. Nesvizhskii, Eun-Mi Hur, Jinlong Yin, Bingyang Shi, Youngwook Kim, Kyung-Sub Moon, Jeong Taik Kwon, Shin Heon Lee, Seung Hoon Lee, Ho Shin Gwak, Anna Lasorella, Heon Yoo, Marc Sanson, Jason K. Sa, Chul-Kee Park, Do-Hyun Nam, Antonio Iavarone, Jong Bae Park
Journal: Cancer Cell (2024)
Mechanical circulatory support for cardiogenic shock: a network meta-analysis of randomized controlled trials and propensity score-matched studies
Authors: Christopher Jer Wei Low, Ryan Ruiyang Ling, Michele Petrova Xin Ling Lau, Nigel Sheng Hui Liu, Melissa Tan, Chuen Seng Tan, Shir Lynn Lim, Bram Rochwerg, Alain Combes, Daniel Brodie, Kiran Shekar, Susanna Price, Graeme MacLaren, Kollengode Ramanathan
Journal: Intensive Care Medicine (2024)
Prevalence and Determinants of Liver Disease in Relatives of Italian Patients With Advanced MASLD
Authors: Serena Pelusi, Luisa Ronzoni, Jessica Rondena, Chiara Rosso, Grazia Pennisi, Paola Dongiovanni, Sara Margarita, Rossana Carpani, Giorgio Soardo, Daniele Prati, Annalisa Cespiati, Salvatore Petta, Elisabetta Bugianesi, Luca Valenti
Journal: Clinical Gastroenterology and Hepatology (2024)

Metabolic dysfunction associated steatotic liver disease (MASLD) has a strong genetic component. The aim of this study was to examine noninvasively the prevalence of MASLD and of advanced fibrosis in relatives of patients with advanced MASLD and the risk factors for liver involvement, with a focus on the contribution of common genetic risk variants.
Impact of Treatment Response on Risk of Serious Infections in Patients With Crohn’s Disease: Secondary Analysis of the PYRAMID Registry
Authors: Dhruv Ahuja, Jiyu Luo, Yuchen Qi, Gaurav Syal, Brigid S. Boland, John Chang, Christopher Ma, Vipul Jairath, Ronghui Xu, Siddharth Singh
Journal: Clinical Gastroenterology and Hepatology (2024)
Eradication of community-onset Methicillin-resistant Staphylococcus aureus carriage: a narrative review
Authors: Annette C. Westgeest, Jaap L.J. Hanssen, Mark G.J. de Boer, Emile F. Schippers, Merel M.C. Lambregts
Journal: Clinical Microbiology and Infection (2024)

BackgroundMethicillin-resistant Staphylococcus aureus (MRSA) colonization increases infection risk in both patients and healthy individuals. Decolonization therapy has been proven to reduce S. aureus infections, but data on the effectiveness of individual decolonization strategies in community-onset MRSA carriage are scarce.ObjectivesThe aim of this narrative review was to summarize the evidence on strategies for the elimination of MRSA colonization in community-onset MRSA carriers.Sources.Pubmed database was searched for studies on MRSA eradication, from inception to July 2023.Content.Topical therapy is proven to be effective in nasal-only carriage and in temporary load reduction. Mupirocin nasal ointment in combination with chlorhexidine body wash is highly effective in nasal-only MRSA carriers in the community as well. In patients with extra-nasal colonization, addition of orally administered antibiotics likely increases success rates compared to topical therapy alone. Studies on systemic treatment of extra-nasal MRSA decolonization are subject to a high heterogeneity of antimicrobial agents, treatment duration, and control groups. The majority of evidence supports the use of a combination of topical therapy with rifampin and another antimicrobial agent. Decolonization treatment with probiotics is a promising novel non-antibiotic strategy. However, achieving long-term decolonization is more likely in countries with low MRSA prevalence, given the risk of recolonization in a context of high MRSA prevalence.Implications.The decision to pursue community-onset MRSA eradication treatment in the individual patient should be based on the combination of the treatment objective (short-term bacterial load reduction in healthcare settings versus long-term eradication in community settings), and the likelihood of successful decolonization. The latter is influenced by both individual risk factors for treatment failure, and the risk of recolonization. The addition of a combination of systemic antibiotics is rational for extra-nasal long-term decolonization. To determine the most effective systemic antimicrobial agents in MRSA decolonization, more research is needed.
Gestational Diabetes and Cardiovascular Health—Reply
Authors: Kartik K. Venkatesh, Sadiya S. Khan, Camille E. Powe
Journal: JAMA (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Improving the transparency and reliability of observational studies through registration
Authors: Florian Naudet, Chirag J Patel, Nicholas J DeVito, Gérard Le Goff, Ioana A Cristea, Alain Braillon, Sabine Hoffmann
Journal: BMJ (2024)

The increasing use of routinely collected data requires transparency and reliability.• This could be done through registration, which needs to consider the level of detail and flexibility that observational research needs.• A centralised repository may reduce redundancy, help users and increase accountability by informing participants about the use of personal data.
Corrections to Results, Figure 2, and Table 3
Journal: JAMA Oncology (2024)

Stuart J. Wong, MD; Pedro A. Torres-Saavedra, PhD; Nabil F. Saba, MD; George Shenouda, MD; Jeffrey M. Bumpous, MD; Robert E. Wallace, PhD; Christine H. Chung, MD; Adel K. El-Naggar, MD, PhD; Clement K. Gwede, PhD, RN; Barbara Burtness, MD; Paul A. Tennant, MD; Neal E. Dunlap, MD; Rebecca Redman, MD; William A. Stokes, MD; Soumon Rudra, MD; Loren K. Mell, MD; Assuntina G. Sacco, MD; Sharon A. Spencer, MD; Lisle Nabell, MD; Min Yao, MD; Fabio L. Cury, MD; Darrion L. Mitchell, MD, PhD; Christopher U. Jones, MD; Selim Firat, MD; Joseph N. Contessa, MD, PhD; Thomas Galloway, MD; Adam Currey, MD; Jonathan Harris, MS; Walter J. Curran Jr, MD; Quynh-Thu Le, MD
Correspondence and comments on American College of Rheumatology and EULAR antiphospholipid syndrome classification criteria: comment on the article by Barbhaiya et al
Authors: Jaume Alijotas‐Reig, Joana Marques‐Soares, Enrique Esteve‐Valverde, Francesc Miró‐Mur, Cristina Belizna, Sebastian Udry, Omar Latino, Raquel Ferrer‐Oliveras, Arsenne Mekinian, Luis Saez‐Comet, Sara de Carolis, Ariella Hoxha, Eleftheria Lefkou, Elisa Llurba, Patrizia Rovere‐Querini, Sara Tabacco, Valentina Canti
Journal: Arthritis & Rheumatology (2024)

Disclosure Form Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Stereotactic Body Radiotherapy in Locally Advanced Non–Small Cell Lung Cancer—Is This the Future?
Authors: Nataniel H. Lester-Coll, Henry S. Park
Journal: JAMA Oncology (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
A Gpr35-tuned gut microbe-brain metabolic axis regulates depressive-like behavior
Authors: Lingsha Cheng, Haoqian Wu, Xiaoying Cai, Youying Zhang, Siqi Yu, Yuanlong Hou, Zhe Yin, Qingyuan Yan, Qiong Wang, Taipeng Sun, Guangji Wang, Yonggui Yuan, Xueli Zhang, Haiping Hao, Xiao Zheng
Journal: Cell Host & Microbe (2024)
Single-cell atlas of healthy human blood unveils age-related loss of NKG2C+GZMB–CD8+ memory T cells and accumulation of type 2 memory T cells
Authors: Marina Terekhova, Amanda Swain, Pavla Bohacova, Ekaterina Aladyeva, Laura Arthur, Anwesha Laha, Denis A. Mogilenko, Samantha Burdess, Vladimir Sukhov, Denis Kleverov, Barbora Echalar, Petr Tsurinov, Roman Chernyatchik, Kamila Husarcikova, Maxim N. Artyomov
Journal: Immunity (2024)

(Immunity 56, 2836–2854.e1–e9; December 12, 2023) The authors noticed that x axis text labels of Temra cells and NKT-like cells were inadvertently swapped in Figures 4F and 4H during the final figure formatting, and it has now been corrected. The corrected figure panel does not affect the conclusions. Additionally, in the gating strategy panel for NK, NKT-like, and T cells in Figure S5A, there was an unintentional swap of the x and y axes labels. The authors corrected the panel, with CD3:BV510 now on the x axis and CD56:BV570 now on the y axis. The authors apologize for any confusion or inconvenience this has caused. Figure 4Changes in composition of CD8+ T cells during healthy aging (original)View Large Image Figure ViewerDownload Hi-res image Download (PPT) Single-cell atlas of healthy human blood unveils age-related loss of NKG2C+GZMB−CD8+ memory T cells and accumulation of type 2 memory T cellsTerekhova et al.ImmunityNovember 13, 2023In BriefTerekhova et al. perform single-cell RNA sequencing on >300 samples between 25 and 85 years to comprehensively profile immune changes throughout aging. This resource revealed 12 subpopulations that change with age, including increased type 2 memory CD4+ and CD8+ T cells and decreased NKG2C+GZMB−CD8+ memory population. Full-Text PDF Open Access
Remembering Eberhard Ritz: A Clinician–Scientist Extraordinaire
Authors: Jochen Reiser, Martin Zeier
Journal: Journal of the American Society of Nephrology (2024)

1President's Office, University of Texas Medical Branch, UTMB, Galveston, Texas 2University Nephrology Center, Ruprecht Karl University of Heidelberg, Heidelberg, Germany Correspondence: Dr. Jochen Reiser, The University of Texas Medical Branch, UTMB, 301 University Boulevard, Galveston, TX 77555, or Dr. Martin Zeier, Ruprecht Karl University of Heidelberg, Im Neuenheimer Feld 162, 69120 Heidelberg, Germany. Email: [email protected] or [email protected]
Federal Regulations and Dialysis-Related Disparities
Authors: Jenny I. Shen, Ladan Golestaneh, Keith C. Norris
Journal: JAMA (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
α-L-iduronidase fused with humanized anti-human transferrin receptor antibody (lepunafusp alfa) for mucopolysaccharidosis type I: A phase 1/2 trial
Authors: Paul Harmatz, Roberto Giugliani, Ana Maria Martins, Takashi Hamazaki, Toru Kubo, Ryutaro Kira, Kohtaro Minami, Toshiaki Ikeda, Hiroaki Moriuchi, Satoshi Kawashima, Naoko Takasao, Sairei So, Hiroyuki Sonoda, Tohru Hirato, Kazunori Tanizawa, Mathias Schmidt, Yuji Sato
Journal: Molecular Therapy (2024)

Mucopolysaccharidosis type I (MPS I) causes systemic accumulation of glycosaminoglycans due to a genetic deficiency of α-L-iduronidase (IDUA), which results in progressive systemic symptoms affecting multiple organs, including the central nervous system (CNS). Because the blood-brain barrier (BBB) prevents enzymes from reaching the brain, enzyme replacement therapy is effective only against the somatic symptoms. Hematopoietic stem cell transplantation can address the CNS symptoms, but the risk of complications limits its applicability. We have developed a novel genetically modified protein consisting of IDUA fused with humanized anti-human transferrin receptor antibody (lepunafusp alfa; JR-171), which has been shown in nonclinical studies to be distributed to major organs, including the brain, bringing about systemic reductions in heparan sulfate (HS) and dermatan sulfate concentrations. Subsequently, a first-in-human study was conducted to evaluate the safety, pharmacokinetics, and exploratory efficacy of JR-171 in 18 patients with MPS I. No notable safety issues were observed. Plasma drug concentration increased dose dependently and reached its maximum approximately 4 h after the end of drug administration. Decreased HS in the cerebrospinal fluid suggested successful delivery of JR-171 across the BBB, while suppressed urine and serum concentrations of the substrates indicated that its somatic efficacy was comparable to that of laronidase.
Geriatric Medicine as a Profession
Authors: Jean-Pierre Michel, Fiona Ecarnot
Journal: JAMA (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Gestational Diabetes and Cardiovascular Health
Authors: Katy J. L. Bell, Paul P. Glasziou, Jenny A. Doust
Journal: JAMA (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Skin microbe-dependent TSLP-ILC2 priming axis in early life is co-opted in allergic inflammation
Authors: Jimin Cha, Tae-Gyun Kim, Euihyun Bhae, Ho-Jin Gwak, Yeajin Ju, Young Ho Choe, In-Hwan Jang, Youngae Jung, Sungmin Moon, Taehyun Kim, Wuseong Lee, Jung Sun Park, Youn Wook Chung, Siyoung Yang, Yong-Kook Kang, Young-Min Hyun, Geum-Sook Hwang, Won-Jae Lee, Mina Rho, Ji-Hwan Ryu
Journal: Cell Host & Microbe (2024)
Insights into <i>Ganoderma</i> fungi meroterpenoids opening a new era of racemic natural products in mushrooms
Authors: Jiao‐Jiao Zhang, Fu‐Ying Qin, Yong‐Xian Cheng
Journal: Medicinal Research Reviews (2024)

Ganoderma meroterpenoids (GMs) containing 688 structures to date were discovered to have multiple remarkable biological activities. 65.6% of meroterpenoids featuring stereogenic centers from Ganoderma species are racemates. Further, GMs from different Ganoderma species seem to have their own characteristics. In this review, a comprehensive summarization of GMs since 2000 is presented, including GM structures, structure corrections, biological activities, physicochemical properties, total synthesis, and proposed biosynthetic pathways. Additionally, we especially discuss the racemic nature, species-related structural distribution, and structure-activity relationship of GMs, which will provide a likely in-house database and shed light on future studies on GMs.
Tafenoquine following G6PD screening versus primaquine for the treatment of vivax malaria in Brazil: A cost-effectiveness analysis using a transmission model
Authors: David J. Price, Narimane Nekkab, Wuelton M. Monteiro, Daniel A. M. Villela, Julie A. Simpson, Marcus V. G. Lacerda, Michael T. White, Angela Devine
Journal: PLoS Medicine (2024)

Malaria transmission modelling has demonstrated the potential impact of semiquantitative glucose-6-phosphate dehydrogenase (G6PD) testing and treatment with single-dose tafenoquine for Plasmodium vivax radical cure but has not investigated the associated costs. This study evaluated the cost-effectiveness of P. vivax treatment with tafenoquine after G6PD testing using a transmission model.
Accelerated Hypofractionated Chemoradiation Followed by Stereotactic Ablative Radiotherapy Boost for Locally Advanced, Unresectable Non–Small Cell Lung Cancer
Authors: Trudy C. Wu, Elaine Luterstein, Beth K. Neilsen, Jonathan W. Goldman, Edward B. Garon, Jay M. Lee, Carol Felix, Minsong Cao, Stephen E. Tenn, Daniel A. Low, Patrick A. Kupelian, Michael L. Steinberg, Percy Lee
Journal: JAMA Oncology (2024)

Intrathoracic progression remains the predominant pattern of failure in patients treated with concurrent chemoradiation followed by a consolidation immune checkpoint inhibitor for locally advanced, unresectable non-small cell lung cancer (NSCLC).